Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

ILX-651 in new phase II trial for hormone-refractory prostate cancer

June 21, 2004

New CDK inhibitors in early development at Banyu

June 18, 2004

Antiangiogenic HARP-derived peptides newly developed at CNRS

June 18, 2004

Labopharm to apply polymeric nanodelivery systems technology to cancer drug

June 18, 2004

Phase II trial of Xcytrin for recurrent low-grade NHL under way

June 18, 2004

Efaproxyn and Revaproxyn, new trade names for efaproxiral

June 18, 2004

OSI and Genentech sign new Tarceva agreements

June 18, 2004

Clinical efficacy of a BAY-43-9006 combination regimen in advanced melanoma

June 18, 2004

First phase IIa patients receive BrachySil for liver cancer

June 17, 2004

Symadex enters phase I in patients with advanced solid tumors

June 17, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...